Resumen:
The worldwide growth of diabetes mellitus (DM) has, in recent years, generated an exponential
increase in associated comorbidities such as high blood pressure, cholesterol, and cardiovascular
risk (CVR), with an increase in mortality in the population (1). At the same time, the global
DM pandemic increased by 75% in recent decades, with a large proportion of affected individuals
spanning all age groups from 1988 to 2010 (2). In the Americas, its prevalence has increased from 5
to 8.3% in recent years, particularly in Honduras, where 6% of individuals over 20 years of age have
DM (3). As such, DM increases health care costs in low- and middle-income nations (4).
Diagnosing diabetes mellitus type 2 (DM2) has changed since the inclusion of glycosylated
hemoglobin (HbA1-c), as it is ¿6.5% in DM2. The criterion for fasting glucose is ¿126 mg/dL,
whereas glucose at 2 h is ¿200 mg/dL (5). A hyperglycemic state can lead to an underlying
prothrombotic environment, an overactivation of the coagulation cascade, fatal thromboembolic
complications, and, eventually, increased mortality in DM patients (6). Medical treatment focuses
on three pillars: drugs, nutrition, and education (7). The use of metformin acts as a standard
pharmacological insulin used by patients to avoid weight gain (8). Nutritional medical therapy
(NMT) prioritizes glycemic control and reduces comorbidities (7, 9). The diet promotion program
is based on dietary guidelines, with group physical activity proving effective for predicting DM2
sowing but ineffective for long term benefits due to the lack of adherence (10). To this effect, the
American Diabetes Association emphasized the need for individualized medical nutritional therapy
(IMNT) (11).
Carbohydrate counting (CCHO) has been shown to be effective for glycemic control in diabetes
mellitus type 1 patients when being intensively treated with insulin (12, 13). Carbohydrate
counting considers the actual content of food consumed based on the individual¿s usual intake
and coordinates insulin-glucose utilization so that both curves act as a single exponentially
flattened growth curve (14). The resulting weight gain is a consequence of decreased urine sugar
loss (15). Few studies have used carbohydrate counting in DM2 in the primary care setting,
and although it showed improvements in HbA1c, compression of carbohydrate counting was
considered difficult for participants (16). Given the paucity of evidence from randomized controlled
clinical trials in Latin American for carbohydrate counting DM2 patients, this work aimed to
evaluate the effectiveness of this medical nutritional treatment, which minimizes the risk of
developing comorbidities and public spending on health care